Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Weekly News Recap #Phispers
1. (2s)-2-((2-((4s)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl)-5,6-dihydroimidazo(1,2-d)(1,4)benzoxazepin-9-yl)amino)propanamide
2. Gdc-0077
1. Gdc-0077
2. 2060571-02-8
3. Rg6114
4. Gdc0077
5. Ro7113755
6. Inavolisib [usan]
7. L4c1uy2nyh
8. (2s)-2-[[2-[(4s)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide
9. (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide
10. Rg-6114
11. Ro-7113755
12. N~2~-{(4s,11ap)-2-[(4s)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl}-l-alaninamide
13. Propanamide, 2-((2-((4s)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-d)(1,4)benzoxazepin-9-yl)amino)-, (2s)-
14. Mfcd31382124
15. Sgeunorsozvtol-cabztgnlsa-n
16. X3n
17. Inavolisib [inn]
18. Unii-l4c1uy2nyh
19. Inavolisib [who-dd]
20. Gtpl9636
21. Chembl4650215
22. Schembl18360780
23. Bdbm295665
24. Amy16810
25. Ex-a2685
26. Nsc800729
27. S8668
28. Us10112932, Compound 101
29. Who 11204
30. Akos040741785
31. At36699
32. Cs-6459
33. Db15275
34. Gdc-0077; Rg6114
35. Nsc-800729
36. Ac-31594
37. Ms-26989
38. Hy-101562
39. A903455
40. Gdc-0077;rg6114;ro-7113755
41. (2s)-2-((2-((4s)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-d)(1,4)benzoxazepin-9-yl)amino)propanamide
42. (2s)-2-({4-[(4s)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-9-oxa-3,6-diazatricyclo[8.4.0.0,tetradeca-1(14),2,4,10,12-pentaen-12-yl}amino)propanamide
43. (s)-2-((2-((s)-4-(difluoromethyl)- 2-oxooxazolidin-3-yl)-5,6- Dihydrobenzo[f]imidazo[1,2- D][1,4]oxazepin-9- Yl)amino)propanamide
44. (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)propanamide (gdc-0077)
Molecular Weight | 407.4 g/mol |
---|---|
Molecular Formula | C18H19F2N5O4 |
XLogP3 | 1.5 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 5 |
Exact Mass | g/mol |
Monoisotopic Mass | g/mol |
Topological Polar Surface Area | 112 |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 641 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Phosphoinositide-3 Kinase Inhibitors
Agents that inhibit PHOSPHOINOSITIDE-3 KINASE activity. (See all compounds classified as Phosphoinositide-3 Kinase Inhibitors.)
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
99
PharmaCompass offers a list of Inavolisib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Inavolisib manufacturer or Inavolisib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Inavolisib manufacturer or Inavolisib supplier.
PharmaCompass also assists you with knowing the Inavolisib API Price utilized in the formulation of products. Inavolisib API Price is not always fixed or binding as the Inavolisib Price is obtained through a variety of data sources. The Inavolisib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Inavolisib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Inavolisib, including repackagers and relabelers. The FDA regulates Inavolisib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Inavolisib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Inavolisib supplier is an individual or a company that provides Inavolisib active pharmaceutical ingredient (API) or Inavolisib finished formulations upon request. The Inavolisib suppliers may include Inavolisib API manufacturers, exporters, distributors and traders.
Inavolisib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Inavolisib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Inavolisib GMP manufacturer or Inavolisib GMP API supplier for your needs.
A Inavolisib CoA (Certificate of Analysis) is a formal document that attests to Inavolisib's compliance with Inavolisib specifications and serves as a tool for batch-level quality control.
Inavolisib CoA mostly includes findings from lab analyses of a specific batch. For each Inavolisib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Inavolisib may be tested according to a variety of international standards, such as European Pharmacopoeia (Inavolisib EP), Inavolisib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Inavolisib USP).